ClinicalTrials.Veeva

Menu
A

Associated Skin Care Specialists | Minnesota Clinical Study Center

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BMS-986165
NFX-179
Upadacitinib
Rapamycin
Secukinumab
Risankizumab
Difamilast
JNJ-77242113
Sofpironium Bromide
LY3009104

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 35 total trials

A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita

PALV-08 is a multicenter, open-label treatment (OLT) study enrolling adults with Pachyonychia Congenita (PC) with genotyped keratin mutations KRT6A,...

Enrolling
Pachyonychia Congenita
Drug: PTX-022

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:*...

Enrolling
Plaque Psoriasis
Drug: ESK-001
Drug: Placebo

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/o...

Active, not recruiting
Plaque Psoriasis
Drug: Placebo
Drug: JNJ-77242113

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoria...

Enrolling
Plaque Psoriasis
Drug: TAK-279

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to...

Invitation-only
Vitiligo
Drug: Upadacitinib
Drug: Placebo

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling
Alopecia Areata
Drug: Upadacitinib
Drug: Placebo

The objective of the trial is to evaluate the safety and efficacy of SM-020 gel 1.0% in subjects with Seborrheic Keratosis (SK) compared to vehicle g...

Enrolling
Seborrheic Keratosis
Drug: SM-020 gel 1.0%
Drug: Vehicle gel

The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face o...

Enrolling
Gorlin Syndrome
Drug: Patidegib Topical Gel with no active patidegib
Drug: Patidegib Topical Gel

This is a Pre-IDE, prospective, multicenter, randomized, parallel-group, double-blind, vehicle- controlled study to evaluate safety and effectiveness...

Enrolling
Distal Lateral Subungual Onychomycosis
Onychomycosis
Device: Nail Genesis DLSO Product
Device: Nail Genesis DLSO Product (vehicle only)

The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or...

Active, not recruiting
Hidradenitis Suppurativa
Drug: secukinumab

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have bee...

Active, not recruiting
Psoriasis
Drug: BMS-986165

The study is designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK following 28 da...

Enrolling
Androgenetic Alopecia
Drug: PP405 Topical Vehicle Gel
Drug: PP405 0.05% Topical Gel

SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of...

Enrolling
Microcystic Lymphatic Malformation
Drug: QTORIN 3.9% Rapamycin Anhydrous Gel

A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with m...

Active, not recruiting
Discoid Lupus Erythematosus
Drug: Placebo/Daxdilimab
Drug: Daxdilimab

Trial sponsors

AbbVie logo
Amgen logo
Janssen (J&J Innovative Medicine) logo
Acrotech Biopharma logo
Bristol-Myers Squibb (BMS) logo
DermBiont logo
Lilly logo
N
P
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems